Adhexil
Ovarian Cysts
OMRIX BiopharmaceuticalsPhase 3Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Ovarian Cysts cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Danazol Centre for Endocrinology and Reproductive Medicine, Italy | Phase 4 | BB |
Letrozole Wake Forest University Health Sciences | Phase 4 | BB |
Ganirelix Assaf-Harofeh Medical Center | Phase 4 | BB |
Cetrotide Zagazig University | Phase 4 | BB |
ROPIVACAINE San Gerardo Hospital | Phase 3 | BB |
View all 13 →
Same molecule, other indications
Adhexil is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →